Please login to the form below

Not currently logged in
Email:
Password:

Briviact

This page shows the latest Briviact news and features for those working in and with pharma, biotech and healthcare.

UCB’s antiepileptic drug gains new US indication

UCB’s antiepileptic drug gains new US indication

UCB’ s antiepileptic drug gains new US indication. FDA approves Briviact as a monotherapy to treat POS. ... The US Food and Drug Administration (FDA) has approved UCB’s Briviact (brivaracetam) CV as a monotherapy treatment option for epilepsy

Latest news

  • SMC gives green light for BMS’ Opdivo SMC gives green light for BMS’ Opdivo

    2014. Additionally, the SMC gave three further approvals to Lundbeck's antidepressant Brintellix (vortioxetine), Novartis' Cosentyx (secukinumab) for ankylosing spondylitis, and UCB's Briviact (brivaracetam) for partial-onset seizures in epilepsy

  • UCB bags FDA approval for epilepsy drug Briviact UCB bags FDA approval for epilepsy drug Briviact

    Billy Dunn, director of the FDA's division of neurology products, said Briviact provides a welcome new treatment option for epilepsy patients. ... The recommended starting dose of Briviact is 50mg or 100mg a day, with a maintenance dose of 50mg to 200mg.

  • UCB wins European approval for epilepsy drug Briviact UCB wins European approval for epilepsy drug Briviact

    UCB wins European approval for epilepsy drug Briviact. Plans first launches within weeks. ... Briviact was submitted for approval in the US in January 2015 but remains under review by the FDA.

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics